1Y Target$107.96Near-term target
5Y Target$130.02Compound horizon
10Y Target$165.96Long-dated conviction
FCF$1.4bTTM · 03/26C+FCF $1.4b — respectable but not differentiating · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+20.9%TTM YoYA-Revenue +20.9% — strong growth, well above S&P median (~7%)
D/E0.01AD/E 0.01 — essentially debt-free, pristine balance sheet
P/E13.7xB+P/E 13.7 — at or below S&P median, reasonable
PEG0.36APEG 0.36 — exceptional; paying well under fair value for growth
Why now
Biotechnology · market cap $19.4b. 13% off the 52-week high of $112.29. Revenue growing +21%, comfortably above the S&P median. PEG 0.36 — paying under fair value for the growth rate. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $107.96 (implying +11% upside).
Moat
Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 31% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 99% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Reimbursement risk — even an approved drug can fail commercially if payors don't reimburse; pricing pressure from Medicare and large PBMs has been accelerating since 2024.
Horizon
1-3 yr $107.96 (24-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $130.02 at ~6% CAGR — dividend + buyback compounding. 10 yr $165.96 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.